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Development of automation for drug discovery
Practical robotics tools were introduced to the analytical
chemistry laboratory about 20 years ago with the devel-
opment of the Zymate I robot by Zymark Corporation
(Hopkington, MA, USA). These tools quickly migrated
within the various parts of the research divisions into
biology and biochemistry laboratories at pharmaceutical
companies to support the new discipline of high-through-
put random screening. These systems were small scale
and often reconﬁgured for new screens because of small
numbers of compounds in collections at that time.
Over the last 10 years, however, these systems have
matured, and it became clear that laboratory automation
was becoming a reliable tool for drug discovery. Over this
period, management in the pharmaceutical research
industry was convinced that this technology and
approach was a productivity enhancing tool and invested
heavily in infrastructure and people to implement it.
During this time, three other trends contributed to the
momentum towards large dedicated ‘industrialized’
screening operations. One was the proliferation of molec-
ular targets that were being produced by the genomics
revolution; the second the move towards detection
technologies that were either homogeneous or semi-
homogeneous eliminating many of the separation steps
in assays; and the third the development of large
combinatorial chemistry/parallel synthesis capability in
the research organizations, often linked to very large-
scale compound collections and compound management
systems.
The result has been the move towards assembly line-like
automation (e.g. Allegro
TM and other conveyer-based
systems) and the move towards ultra-miniaturization and
ultrahigh throughput (e.g. Evotec and Aurora). As a
result, the use of workstation and smaller ﬂexible auto-
mation approaches has largely remained localized within
biotechnology companies or therapeutic biology units
with the larger pharmaceutical organizations where large
support groups or capital to support these large dedicated
automation systems do not exist.
Decline in approval in new chemical
entities as drugs
However, despite trends to make chemistry in lead opti-
mization more eﬃcient (‘kill early and kill often’), it is
clear from a number of seminal presentations over the
last year or so [1, 2] that the promise of industrialized
HTS has not been fulﬁlled, and that the numbers of new
chemical entities being approved (NCEs) has declined
over the last few years, rather than increased. This is true
despite the increased R&D investment in research and in
particular in HTS drug-discovery groups.
These same analysts are now reassessing whether or not
continued investment in traditional HTS can bring
about the revolution in NCE discovery that had been
promised from this investment in resources [3].
What are the explanations for this dearth of NCEs? A
number of suggestions have been put forward (including
the suggestion that we have not had time for the new
drugs from the HTS revolution to make it through the
regulatory pipeline), but the most likely reason is that the
drug-discovery paradigm has been transformed. It is
increasingly being focused on large numbers of single
molecular targets. Also the ‘industrialization’ of HTS has
contributed to the momentum towards screening targets
that are easy to pursue rather than ones that are the most
biologically relevant.
For example, this reliance on single, speciﬁc molecular
targets, such as GPCR subtypes, yield very highly potent
and speciﬁc compounds, but they do not provide the
desired physiological result in vivo. This is especially true
in the central nervous system (CNS), where GPCRs that
have been targeted by very highly speciﬁc and potent
compounds in vitro, but these compounds have turned out
to be ineﬀective in man. Aripiprazole is one example of a
recently approved CNS active compounds that is
eﬀective in vivo, and is one that shows mixed receptor
activity. The use of mixed serotonin/norepinephrine
reuptake inhibitors are other examples of drugs that are
more eﬀective than compounds that target either of the
individual reuptake system alone.
Another probable reason is that early combinatorial
chemistry programs produced large numbers of
compounds that could be easily made rather than the
eﬀort being used to generate ‘druggable’ molecules, i.e
quantity over quality. The trend is now towards more
intelligent library design, but even now parallel synthesis
is still producing compounds that have inherent ﬂaws
in ADMET parameters such as poor solubility, poor
absorption, drug–drug interactions and susceptibility to
ﬁrst-pass metabolism. In vitro and in silico tools to ‘fail fast’
compounds from parallel synthesis programs are being
applied but they need to move towards the application
of these methods in the design of primary screening
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73libraries, in addition to their application to lead optimi-
zation stages.
A third likely reason is the momentum towards the use of
mix and measure primary screening assays. This has lead
to the use of targets that can be easily established, rather
than a consideration of whether these are relevant
targets. Although many of them are, in fact, speciﬁc
single ‘druggable’ molecular targets, they are the ‘low
hanging fruit’ of target classes. Over the last 10 years, this
‘fruit’ has been extensively harvested (e.g. GPCRs,
kinases, proteases, ion channels), and whilst examples of
these still remain as potential targets, most have been
extensively exploited. These classes also represent some of
the last examples of therapeutic intervention at targets
where there can be seen to be a linkage between cause
and eﬀect. However, this target focus is rapidly reaching
the point of diminishing returns as it is understood that
many of the remaining orphan receptors are involved in
complex interactions.
In addition, whilst it is possible to screen in cell-based
systems using the ‘industrialized’ approach, this is not
typically done using these ultrahigh-throughput auto-
mated approaches.
Looking towards the future: high
information-content screens
Collectively, then, this move towards large-scale
and ultrahigh throughput has been facilitated by the
availability of cloned single molecular targets from
the genomics revolution, the explosion in compounds
available for screening through automated combinatorial
and parallel chemical synthesis and the commer-
cialization of generic homogeneous and semi-homoge-
neous mix and measure reagents and detection
technologies.
However, the diseases that have the most unmet medical
need are those that are the most complex (e.g. diabetes,
obesity, mental illness). These complex diseases are the
result of interactions of many diﬀerent regulatory and
feedback systems that translate the eﬀects of multiple
genes on an individual’s susceptibility to a disease, its
severity and progression with environmental inﬂuences
and triggers. If we consider a systems biology approach,
then it is likely that new treatments will come from
a polyvalent eﬀect of new drugs, i.e. an eﬀect in which
a single compound aﬀects multiple cellular processes,
yielding the desired therapeutic eﬀect. It is also likely
that the targets for such compounds are more likely to be
intracellular signalling nodes in pathways that act on
gene expression patterns that inﬂuence the downstream
processes. This would also help to explain the delayed
onset of action of many CNS agents, where one can
imagine that gene expression changes are followed by
modulation of protein expression as the ultimate cellular
event, rather than the immediate eﬀect of these
compounds on cell surface receptors. In order ultimately
to understand these diseases, it will be necessary to
unravel and integrate the systems biology involved.
However, from a drug-discovery perspective, the impor-
tant message to be taken from this concept is that a
systems biology approach to screening is needed, and that
this holds better promise for discovery of truly novel
therapeutics for treatment of these complex disorders.
Often these diseases are currently being treated with
poly-pharmacology, e.g. in mental illness or in obesity,
and a paradigm shift toward the use of polyvalent drugs
may be a solution to this problem of using multiple drugs
in a poly-pharmacologic approach.
All this suggests that an approach needs to be developed
that is both novel and, for example, directed towards
measuring the eﬀect of gene expression when searching
for novel therapeutics. This is the direction that we are
pursuing at Psychiatric Genomics, Inc. We are are also
tackling this problem by using in vitro cell-based screening
systems rather than isolated biochemical targets. These
types of screens measure many parameters simulta-
neously, and thus they will be very information rich
with the potential for yielding both better information
on the eﬀects of compounds on multiple targets simulta-
neously and have the potential for the discover of novel
therapeutics more rapidly.
Drug discovery using the Multi-Parameter
High Throughput Screen (MPHTS
SM)
As indicated above, Psychiatric Genomics is using gene
expression assays to approach the complex psychiatric
diseases of bipolar, schizophrenia and depression. The
platform technology being used relies on measuring the
mRNA expression levels of 16 genes simultaneously in a
single well of a microplate after cells have been treated
with test compounds from a screening library. The results
obtained contribute a pattern of readout of gene
expression that can be considered as a signature for that
particular compound in the particular assay.
To develop gene expression signatures for the screens
based on this platform, we obtain the screening signature
by combining information from three complementary
approaches coupled with a critical biostatistical analysis
of gene expression data. For psychiatric diseases, the
ﬁrst approach uses human post mortem brain tissue
(speciﬁcally quality controlled for PMI, state on death,
age matching, medical diagnosis, RNA quality) to mea-
sure gene expression patterns in normal versus diseased
individuals (bipolar, schizophrenia, depression). We
then extract the diﬀerential pattern of gene expression
and validate this statistically by using signatures from
populations of individuals. The relevant changes are then
validated by RT-PCR. The second approach uses the
gene signature obtained in human neuronal cells treated
with therapeutic agents in vitro compared with untreated
cells. Again a diﬀerential gene expression signature
is obtained, and again is validated by RT-PCR.
The third approach uses the in vivo treatment of animals
with therapeutic agents and obtains a diﬀerential gene
expression signature in diﬀerent animal brain areas
between control and treated animals. These three diﬀer-
ential gene expression signatures are compared and
combined with a biochemical pathway analysis results
in the selection of genes for the MPHTS
SM array.
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The multiparameter approach that Psychiatric Geno-
mics is using is high in information content, but is also
very complex to implement. A description of the assay
protocol will been given in detail in another paper at
this conference [4], but to summarize, cells are treated
for 24h with test compound in a standard tissue culture
microplate and then after incubation under standard
conditions are lysed with a buﬀer containing nuclease
protection probes. These DNA probes then hybridize
with the mRNAs of interest. The solution is then treated
with S1 nuclease to remove all single-stranded nucleic
acids, but leaves the mRNA sequences and DNA pro-
tection probes protected in this double-stranded format.
A subsequent alkaline treatment then degrades the
mRNA and leaves the DNA probes both intact and
matching the quantity of the original mRNA in the cell
lysates. Excess non-duplexed probe has been destroyed
in the nuclease treatment. The detection plates are
prepared separately. These plates contain the 16-gene
probe mini-arrays at the bottom of the wells of a special
96-well microplate. They are treated with sandwich
nucleotide detection sequences, and the detection sand-
wich built up on each of the 16 spots in the well.
Subsequently, an aliquot of the lysed cell extract
containing the nuclease protected mRNA double-
stranded hybrids is added to the detection plates, heated
to allow the melting of the protection duplex and cooled
to allow subsequent hybridization to the capture probes.
Following washing, an additional step hybridizes an
enzyme-labelled detection probe to the sandwich,
followed by the generation of a chemiluminesce signal
by addition of substrate, which is read with a cooled
CCD camera.
Learning from the past (back to the future!)
The successful management of the automation for such
an assay in a biotechnology company environment has
resulted in a return to the ﬂexible philosophy of labora-
tory automation that had been practised in the early days
of the implementation of robotics for high-throughput
screening.
In these early days of laboratory automation, the acces-
sories for the various unit operations of an assay were
often not available and had to be built from scratch. In
addition, it became clear that certain unit operations
were not robot ‘friendly’ and that the goal of achieving
complete assay automation was either impossible
or meant adjusting the assay procedure to a new protocol
with consequent revalidation of the assay. Nevertheless,
using a combination of semibatch automation and
manual intervention satisfactory progress towards high-
throughput screening goals was achieved. This type
of semibatch automation became anathema to many of
the practitioners of industrialized automation, and
thus fell out of favour. However, what was true then
is true now when we want to implement these novel
high-information content screens with a reduced but
more focused and smaller compound libraries.
Then, as now, since throughputs in high-throughput
screening groups were not large, and often because
compound collections even at major pharmaceutical
companies were small, historically this frequently meant
that the robot systems were continually being reconﬁg-
ured as assays came and went during the attrition process
in the screening group, and required a cadre of people
with special talents who could cope with the need for
systems that required this constant attention.
An example of the semibatch type of operation was used
in early cell-based assays, such as the cytotoxicity
screens set up in the early days of automation by my
(then) group at Bristol-Myers Squibb. In this system,
additions of test compounds to the microplates contain-
ing the growing cells were automated using a large
tracked system containing staging CO2 incubators.
The overnight growth was performed oﬀ-line by manual
removal of the plates from the staging incubators, and
the plates with cells returned to the system for
processing for measurement of cell viability after 24 or
48h growth, again this return process being a manual
step. This type of semibatch operation is especially well
suited to high-volume cell-based screens, where it is
undesirable to tie up limited robotic resources just
for storage and incubation for long periods. The
throughput of cell-based assays often is lower than
traditional homogeneous single molecular target assays.
However, when optimized, throughputs can still be
quite considerable and adequate for high-priority
important targets.
We had many of the same challenges automating this
assay as I did with these previous cell-based assays. The
need to maintain sterility is important during the growth
phase of the cells, but the current assay has the
complication that we cannot use antibiotics to maintain
sterility, because of the eﬀects that exposure to these
compounds has on gene expression. This means that
special precautions and process operations are needed
to ensure sterile operation. In addition, the times
involved in the various steps vary widely, the basic
manipulations are more complex than are usual
(i.e. there are a number of high temperature nucleic acid
hybridizations steps involved, plus associated wash steps,
followed by addition of chemiluminescence reagents
and a time-dependant light signal readout) and commer-
cial high-temperature ovens that were compatible with
automation were not available.
Despite these challenges, and following their solution by
means outlined below, the ﬁnal screening throughput is
comparable with some other complex cell-based assays
such as the intracellular measurement of calcium using
ﬂuorescent dyes and the FLIPR
TM (Molecular Devices,
Sunnyvale, CA, USA). At NPS Pharmaceuticals (Salt
Lake City, UT, USA), for example, my (then) screening
group routinely ran 65 96-well plates/day in an entirely
manual mode, assisted by some liquid-handling work-
stations for sample preparation. Once fully operating, our
multiplexed gene expression assay should reach compara-
ble throughput, and thus would be adequate to screen
rapidly quite large-sized compound collections at about
32000 compounds/month.
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(back to the future – part II!)
We required a system that was both state-of-the-art and
able to be conﬁgured to work in a semi-automated
fashion. Since we were using a cell-based assay with a
minimicroarray-based detection system that required
quite long incubation times, this was incompatible with
the utilization of valuable robotic resources for the cell
growth steps. In addition, just as in the early days, the
need to use the system for both assay development
and walk up utilization of the peripherals for other
non-array-based assays (with a limited budget) pre-
cluded complete duplication of the peripherals on the
robotic system. We thus needed to include multiuse into
the design of the system.
As described, this is not the typical mix and read
homogeneous reaction that can be easily automated at
ultrahigh throughput! So careful management of the
decisions about what sort of automation to employ was
essential to establishing a successful high-throughput
screening paradigm.
One of the initial choices to be made was whether to take
a workstation, dedicated automation or integrated, yet
ﬂexible automation approach. The decision to go with a
integrated, ﬂexible robotic system based on a CRS
tracked robotic arm was partly dictated by the fact that
whilst we were in the process of establishing automation
for other internal screens (GPCRs) we did not know the
exact assay protocol for the MPHTS
SM system. Thus, we
chose the CRS system based on our ability to use it as an
integrated robotic platform, but also viewed it as an
integrated single workstation as necessary. It also had
the advantage that our automation support personnel
had extensive experience with the system and was able to
use the scheduler later to assist in workﬂow optimization.
The choice of peripherals was also based on the need to
use these on an open access basis during assay devel-
opment for the MPHTS
SM as well as our other single
target GPCR assays.
Managing the automation not only has required us to
examine carefully the workﬂows through the system to
optimize throughput, but also has required us to inte-
grate the automation of a CCD camera system originally
designed for one-shot manual operation. Fortunately,
we had the staﬀ able to design and construct a custom
automated solution to feed plates from the robot to the
camera. Also, the judicious use of a summer intern
programme allowed us to develop software that allowed
for automated image capture and analysis has allowed us
remove this bottleneck to the HTS process.
These two approaches to developing solutions is again
reminiscent of the early days of high-throughput auto-
mated system development that allowed a system to
evolve from prototype to robust implementation through
skilled system design and construction.
My experience with other automated cell-based systems
at Bristol-Myers Squibb and at NPS Pharmaceuticals
ensured that we focused on the integration of other
workﬂow processes to ensured that the system works
without bottlenecks. These included the development
of a robust system for routinely producing cells in
the correct physiological stage for the assay in large
quantities, the compound and plate management tools
for maximizing the hit rate and retest process, and
the development of advanced data analysis methods
to handle the large quantities of multiparametric data
produced by this high information content screen.
Results and data processing
The results returned from this type of screen are a very
complex and information-rich data set. The system is
designed to screen compounds that aﬀect a multiplexed
gene expression pattern in a highly parallel fashion, and
its early implementation with a six-gene assay has iden-
tiﬁed compounds that mimic the gene expression eﬀect of
a marketed bipolar therapeutic. It has demanded that we
not only use an industrial-strength database to store the
results (ActivityBase, IDBS, Guildford, UK), but also
even with this database the challenges in constructing
templates to upload and analyse data from a complex
multiparameter screen are enormous, since the database
is essentially designed to handle univariate data. This has
meant that we have had to develop and implement tools
that can analyse data in a multidimensional result space.
Of the multiple gene probes in the mini-arrays in the
bottom of each microplate well, some genes are ‘test’
genes and reveal the eﬀect of the compound on the up or
down regulation (or no eﬀect on regulation) of that
particular gene. Since we have started with a proﬁle of
gene expression levels as the target cut-oﬀ in the assay, we
can easily identify compounds that meet the criteria for
the signature. In addition, we can mine the data set for
gene expression pattern changes that can yield com-
pounds that can be useful both as tools to explore the
biochemistry of these events, or as a drug for a disease
where a compound producing a diﬀerent signature
is desired. As we continue to add MPHTS
SM screens to
our portfolio, the data warehouse being build rapidly
builds in value and can be mined for future signature
targets without having to screen physically the entire
compound deck.
Ongoing assay optimization and management
There are tradeoﬀs to be made using this technology.
The cost per assay plate is high compared with assays in
traditional format, but the cost per datum point is not
inconsistent with other complex HTS being run using
expensive, rare reagents. However, experience suggests
that both volume usage and incremental improvements
in the technology will drive costs down signiﬁcantly. This
has been our experience in the past as any pioneering
assay technology becomes more mature.
Meanwhile, measures can be taken to improve the cost/
beneﬁt of the MPHTS
SM. One is to use the power of
chemo-informatics to prioritize plate management
through the screen to maximize SAR information from
primary screening. We have seen an example of how this
might be done, using the earlier six-gene version of the
MPHTS
SM system. We were able to do a similarity
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used in the assay validation to prioritize a small set of
compounds plates to be screened ﬁrst in the assay. From
two ‘hits’ obtained from one of these plates, we prior-
itized an additional set of compound library plates based
on a reﬁned structure similarity match and increased
the ‘hit’ rate threefold. One continuing challenge for us is
to implement the necessary compound management
resources to utilize this approach fully. With more eﬀec-
tive compound management systems, other people have
used in silico techniques to cluster screening compounds,
to select a subset of the compounds as being repre-
sentative of the clusters, re-plate and reformat these into
smaller screening sets. Follow up of ‘hits’ by retesting
nearest neighbours resulted in an increased hit rate in this
secondary round. Frank Brown at Merck [5] has shown
that with this approach one need only screen about 20%
of a collection to get about 95% of the ‘hits’. This can
provide early entry to chemistry even if ultimately the
entire compound collection is screened, but allows the
option to reduce screening costs by 75% if needed.
Much of the ongoing management of the automation
process is focused on three areas. The ﬁrst is acute and
chronic risk management. This is focusing on which part
of the process is so critical that failure of the equipment
would lead to either short- or long-term downtime for the
assay, and the back up procedures to minimize both of
these eﬀects. It also includes an analysis of how to process
samples to minimize the eﬀect of system failure on
individual sample batches on both a short- and long-term
basis. The second area is focus on throughput optimiza-
tion. This is directed toward an analysis of the use of
either workﬂow processes or equipment additions to
increase the throughput of the assay. One area of atten-
tion here is the complexity and amount of data being
generated and how to improve both data processing
and the use of novel data analysis and visualization
techniques to aid chemistry follow up of ‘hits’. The third
is not related to automation but to two critical parts of
the protocol, i.e. tissue culture and assay step optimiza-
tion. One of the lessons well learned over the years is
that the automation process is not necessarily the weakest
link in the chain, but that control of cell growth state is
critical to ensure a reproducible supply of cells at a
particular stage of biological responsiveness and that
careful optimization of each stage of an assay process
to ensure that each assay step is not balanced at a
knife point of response condition to allow some window
of process condition which does not result in great
variations in output of the process stage.
The measurement of mRNA expression of multiple genes
in a cell-based assay, with multiple process steps for
expression level detection, makes this a very diﬃcult
assay to develop into an industrialized high-throughput
screen. My previous experience with the measurement of
intracellular calcium changes in HEK-293 cells trans-
formed with recombinant mGluRs using the FLIPR
assay at NPS Pharmaceuticals indicated that the state
of cell physiology of the recombinant cells was very
important for receptor expression and physiological
response of the cells. This multiplexed gene expression
assay multiplies these considerations many fold. Critical
for success in our current assay has been the development
of robust QC procedures for measurement of the state
of cell physiology both prior to treatment of the cells
with compound and also as a QC check for a decision
point to commit to the use of the cell lysates in the
detection part of the assay.
Summary
We believe that this approach to high-throughput
screening not only will yield more eﬀective and novel
therapies for psychiatric disease, but also will do it in a
more eﬀective and rapid manner, one that will overtake
traditional single-target HTS approaches.
The system that we have put together based on
experience in developing ﬂexible, small-scale and recon-
ﬁgurable automation shows that the future of high-
content cell-based assays can be achieved with limited
resources and without the need for large-scale ‘industrial’
automation and suggests that the future of drug discovery
lies less with huge, inﬂexible ‘industrialized’ systems
than more nimble ﬂexible automation. Just as the
PC destroyed the mainframe, and just as the Internet
destroyed point-to-point telecommunications, will ﬂex-
ible automation destroy industrialized high-throughput
screening or will they coexist as mainframes as the
telephone coexists with PCs and the Internet?
However, the results achieved to date with our 6-gene
MPHTS
SM system suggest that a multiparametric
approach to drug discovery has the potential to be a
more eﬀective approach to the discovery of therapeutic
agents acting at unique sites and with novel mechanisms
of action.
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